
|Articles|September 1, 2022
US-based development, testing and fill/finish capacity is now available
Author(s)August Bioservices
Since 2020, the CDMO landscape has undergone significant changes. Dearth of fill/finish capacity in the US, exacerbated by COVID and vaccine production, caused market dislocation but also opportunity. With insights gathered through a blind, independent “voice of the customer” industry survey, discover what over 300 decision makers had to say about post-COVID trends and outsourcing plans. Among the intriguing responses captured in the survey – nearly 80% of respondents expressed they were open to, or actively looking for, new CRO/CDMO partners over the past 12 months.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Trending on Pharmaceutical Technology
1
Women in STEM: Early Phase Drug Development
2
Drug Digest: Outsourcing Partnerships Fuel Global Biopharma Discovery and Scale-Up
3
FDA Grants Priority Review For Pfizer’s Marstacimab for Hemophilia A or B
4
PharmTech Weekly Roundup - February 6, 2026
5